Compare · RVTY vs TXG
RVTY vs TXG
Side-by-side comparison of Revvity Inc. (RVTY) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $9.68B, about 3.4x TXG ($2.84B).
- Over the past year, RVTY is down 6.8% and TXG is up 172.9% - TXG leads by 179.7 points.
- TXG has been more active in the news (7 items in the past 4 weeks vs 6 for RVTY).
- TXG has more recent analyst coverage (25 ratings vs 18 for RVTY).
- Company
- Revvity Inc.
- 10x Genomics Inc.
- Price
- $86.67+5.21%
- $22.05+9.16%
- Market cap
- $9.68B
- $2.84B
- 1M return
- -1.16%
- +3.91%
- 1Y return
- -6.77%
- +172.90%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 7
- Recent ratings
- 18
- 25
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest RVTY
- Revvity Board Declares Quarterly Dividend
- SEC Form 4 filed by Gonzales Anita
- Revvity to Present at Upcoming Investor Conferences
- Revvity downgraded by Barclays with a new price target
- Revvity to Hold Earnings Call on Tuesday, May 5, 2026
- Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
- SEC Form 4 filed by Gonzales Anita
- SEC Form DEFA14A filed by Revvity Inc.
- SEC Form DEF 14A filed by Revvity Inc.
- Officer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)
Latest TXG
- 10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
- SEC Form DEFA14A filed by 10x Genomics Inc.
- SEC Form DEF 14A filed by 10x Genomics Inc.
- 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
- SEC Form 4 filed by Saxonov Serge
- 10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
- 10x Genomics upgraded by William Blair
- SEC Form 4 filed by Saxonov Serge
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.